• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Interim analyses for monitoring clinical trials that do not materially affect the type I error rate.

作者信息

Gould A L

机构信息

Merck, Sharp, and Dohme Research Laboratories, West Point, PA 19486.

出版信息

Stat Med. 1992 Jan 15;11(1):55-66. doi: 10.1002/sim.4780110107.

DOI:10.1002/sim.4780110107
PMID:1557576
Abstract

Monitoring clinical trials often requires examining the interim findings to see if the sample size originally specified in the protocol will provide the required power against the null hypothesis when the alternative hypothesis is true, and to increase the sample size if necessary. This paper presents a new method, based on the overall response rate, for carrying out interim power evaluations when the observations have binomial distributions, without unblinding the treatment assignments or materially affecting the type I error rate. Simulation study results confirm the performance of the method.

摘要

相似文献

1
Interim analyses for monitoring clinical trials that do not materially affect the type I error rate.
Stat Med. 1992 Jan 15;11(1):55-66. doi: 10.1002/sim.4780110107.
2
Statistical inference for self-designing clinical trials with a one-sided hypothesis.
Biometrics. 1999 Mar;55(1):190-7. doi: 10.1111/j.0006-341x.1999.00190.x.
3
Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.使用期中 Z 值或置信限控制 I 型和 II 型错误概率的无效性期中监测。
Clin Trials. 2009 Dec;6(6):565-73. doi: 10.1177/1740774509350327. Epub 2009 Nov 23.
4
Sample size determination using an interim analysis.使用期中分析确定样本量。
J Biopharm Stat. 1993 Sep;3(2):159-66. doi: 10.1080/10543409308835057.
5
Optimal conditional error functions for the control of conditional power.用于控制条件功效的最优条件误差函数。
Biometrics. 2004 Sep;60(3):715-23. doi: 10.1111/j.0006-341X.2004.00221.x.
6
Comparison of a two-stage and three-stage interim-analysis procedure.两阶段和三阶段中期分析程序的比较。
Psychol Rep. 1992 Aug;71(1):3-14. doi: 10.2466/pr0.1992.71.1.3.
7
Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.基于有前景的中期结果的样本量调整及其在确证性临床试验中的应用。
Clin Trials. 2015 Dec;12(6):584-95. doi: 10.1177/1740774515594378. Epub 2015 Jul 20.
8
Planning and revising the sample size for a trial.
Stat Med. 1995;14(9-10):1039-51; discussion 1053-5. doi: 10.1002/sim.4780140922.
9
Design for sample size re-estimation with interim data for double-blind clinical trials with binary outcomes.具有二元结局的双盲临床试验中利用期中数据进行样本量重新估计的设计。
Stat Med. 1997 Sep 15;16(17):1913-23. doi: 10.1002/(sici)1097-0258(19970915)16:17<1913::aid-sim610>3.0.co;2-z.
10
The reassessment of trial perspectives from interim data--a critical view.基于中期数据对试验前景的重新评估——批判性观点。
Stat Med. 2006 Jan 15;25(1):23-36. doi: 10.1002/sim.2180.

引用本文的文献

1
Sample size recalculation based on the overall success rate in a randomized test-treatment trial with restricting randomization to discordant pairs.在一项将随机化限制在不一致配对的随机试验治疗试验中,基于总体成功率进行样本量重新计算。
BMC Med Res Methodol. 2025 Mar 18;25(1):74. doi: 10.1186/s12874-024-02410-3.
2
ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic.ACTIV试验:在突发大流行背景下试验设计中吸取的经验教训。
J Clin Transl Sci. 2024 Oct 15;8(1):e151. doi: 10.1017/cts.2024.1. eCollection 2024.
3
Sample Size Reestimation in Stochastic Curtailment Tests With Time-to-Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters.
在非比例风险情况下,利用两个形状参数未知的威布尔分布,对具有事件发生时间结局的随机截尾试验进行样本量重新估计。
Pharm Stat. 2025 Jan-Feb;24(1):e2429. doi: 10.1002/pst.2429. Epub 2024 Aug 18.
4
A diagnostic phase III/IV seamless design to investigate the diagnostic accuracy and clinical effectiveness using the example of HEDOS and HEDOS II.采用 HEDOS 和 HEDOS II 示例的 III/IV 期无缝设计诊断研究,以评估其诊断准确性和临床效果。
Stat Methods Med Res. 2024 Mar;33(3):433-448. doi: 10.1177/09622802241227951. Epub 2024 Feb 7.
5
Sample size recalculation based on the prevalence in a randomized test-treatment study.基于随机试验-治疗研究中患病率的样本量重新计算。
BMC Med Res Methodol. 2022 Jul 25;22(1):205. doi: 10.1186/s12874-022-01678-7.
6
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.在日本 2 型糖尿病伴微量白蛋白尿患者中评估卡格列净疗效的研究(CANPIONE 研究)的背景、设计和基线特征。
Diabetes Obes Metab. 2022 Aug;24(8):1429-1438. doi: 10.1111/dom.14731. Epub 2022 May 18.
7
Nordic study on human milk fortification in extremely preterm infants: a randomised controlled trial-the N-forte trial.北欧关于极低出生体重儿母乳强化的研究:一项随机对照试验——N-forte 试验。
BMJ Open. 2021 Nov 23;11(11):e053400. doi: 10.1136/bmjopen-2021-053400.
8
Design aspects of COVID-19 treatment trials: Improving probability and time of favorable events.COVID-19 治疗试验的设计方面:提高有利事件的概率和时间。
Biom J. 2022 Mar;64(3):440-460. doi: 10.1002/bimj.202000359. Epub 2021 Oct 22.
9
Effect of Intraoperative High Positive End-Expiratory Pressure (PEEP) With Recruitment Maneuvers vs Low PEEP on Postoperative Pulmonary Complications in Obese Patients: A Randomized Clinical Trial.术中高呼气末正压(PEEP)联合复张手法与低 PEEP 对肥胖患者术后肺部并发症的影响:一项随机临床试验。
JAMA. 2019 Jun 18;321(23):2292-2305. doi: 10.1001/jama.2019.7505.
10
Wearable Cardioverter-Defibrillator after Myocardial Infarction.心肌梗死后的可穿戴式心脏除颤器。
N Engl J Med. 2018 Sep 27;379(13):1205-1215. doi: 10.1056/NEJMoa1800781.